LCK and type 1 diabetes mellitus: In addition, therapies targeting LCK have been shown to promote/inhibit T-cell growth and development in a variety of diseases such as type 1 diabetes, colon cancer, asthma, and organ transplant rejection, thereby altering disease outcomes (Sabat et al., 2006; Gholamin et al., 2015).